Transforming growth factor β type II receptor as a marker in diffuse large B cell lymphoma

Tumor Biology

Volumn 36, Issue 12, 2015, Pages 9903-9908

  Mao, Shudan ^a   Yang, Wenqi ^a   Ai, Limei ^a   Li, Zhe ^a   Jin, Jieping ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Diffuse large B cell lymphoma; Survival; TGF RII

Indexed keywords

LACTATE DEHYDROGENASE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; TUMOR MARKER; UNCLASSIFIED DRUG; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR;

ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; FEMALE; FOLLOW UP; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; TGFBETAR2 GENE; AGED; BIOSYNTHESIS; GENETICS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

ADULT; AGED; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84951279920     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3700-z     Document Type: Article

References (44)

1. Swerdlow SH, Campo E, Harris NL, et al., editors. World Health Organization classification of tumours of haematopoietic and lymphoid tissues (edition 4). Lyon: International Agency for Research on Cancer Press; 2008.
2. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–95.
3. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–92.
4. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol. 1999;111:S8–S12.
5. Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d’Etudes des Lymphomes Agressifs. J Clin Oncol. 1991;9:211–9.
6. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin’s lymphoma. Groupe d’Etude des Lymphomes de l’Adulte (GELA). Blood. 1996;87:265–72.
7. Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a populationbased study. J Clin Oncol. 1996;14:2131–8.
8. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin’s lymphoma: a British National Lymphoma Investigation Study. Blood. 1996;88:1046–51.
9. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997;90:244–51.
10. Koduru PR, Raju K, Vadmal V, et al. Correlation between mutation in p53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin’s lymphoma. Blood. 1997;90:4078–91.
11. Ichikawa A, Kinoshita T, Watanabe T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med. 1997;337:529–34.
12. Zhang H, Gao J, Zhao Z, Li M, Liu C. Clinical implications of SPRR1A expression in diffuse large B-cell lymphomas: a prospective, observational study. BMC Cancer. 2014;14:333.
13. Liu C, Lu Y, Wang B-b, Zhang Y-j, Zhang R-s, Lu Y, et al. Clinical implications of stem cell gene Oct-4 expression in breast cancer. Ann Surg. 2011;253:1165–71.
14. Liu C, Cao X, Zhang Y, Xu H, Zhang R, Wu Y, et al. Co-expression of Oct-4 and Nestin in human breast cancers. Mol Biol Rep. 2012;39:5875–81.
15. Xu D, Xu H, Ren Y, Liu C, Wang X, Zhang H, et al. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One. 2012;7(10):e46670.
16. Hao Zhang, Yuan Ren, Huanming Xu, Deyan Pang, Chao Duan, Caigang Liu. The expression of stem cell protein Piwil2 and piR-932 in breast cancer. 2013 Aug 27. pii: S0960-7404(13)00066-2.
17. Liu B, Nicolaides NC, Markowitz S, Willson JKV, Parsons RE, Jen J, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet. 1995;9:48.
18. Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor NM, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 1996;56:4836.
19. Umar A, Boyer JC, Thomas DC, Nguyen DC, Risinger JI, Boyd J, et al. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J Biol Chem. 1994;269:14367.
20. Boyer JC, Umar A, Risinger JI, Lipford JR, Kane M, Yin S, et al. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res. 1995;55:6063.
21. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair defective human tumor cell lines. Cancer Res. 1997;57:808.
22. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95:6870.
23. Simpkins SB, Bocker T, Swisher EM, Mutch DG, Gersell DJ, Kovatich AJ, et al. hMLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet. 1999;8:661.
24. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, et al. Inactivation of the type II TGFβ receptor in colon cancer cells with microsatellite instability. Science. 1995;268:1336.
25. Yamamoto H, Sawai H, Perucho M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1997;57:4420.
26. Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997;275:967.
27. Schwartz Jr S, Yamamoto H, Navarro M, Maestro M, Reventos J, Perucho M. Frameshift mutations at mononucleotide repeats in caspase-5 and other target genes in endometrial and gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res. 1999;59:2995.
28. Stansfeld AG, Diebold J, Noel H, et al. Updated Kiel classification for lymphomas. Lancet. 1988;1:292–3.
29. Isufi I, Seetharam M, Zhou L, Sohal D, Opalinska J, et al. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. J Interferon Cytokine Res. 2007;27:543–52.
30. Santibanez JF, Quintanilla M, Bernabeu C. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin Sci (Lond). 2011;121:233–51.
31. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 1992;71:1003–14.
32. Derynck R, Zhang Y. Smad-dependent and Smad-independent pathways in TGF-family signalling. Nature. 2003;425:577–84.
33. Reiss M. TGF-beta and cancer. Microbes Infect. 1999;1:1327–47.
34. Rehmann JA, LeBien TW. Transforming growth factorbeta regulates normal human pre-Bcell differentiation. Int Immunol. 1994;6:315–22.
35. Kehrl JH, Thevenin C, Rieckmann P, et al. Transforming growth factor-beta suppresses human Blymphocyte Ig production by inhibiting synthesis and the switch from the membrane form to the secreted form of Ig mRNA. J Immunol. 1991;146:4016–23.
36. Smeland EB, Blomhoff HK, Holte H, et al. Transforming growth factor type beta (TGF beta) inhibits G1 to S transition, but not activation of human Blymphocytes. Exp Cell Res. 1987;171:213–22.
37. Bouchard C, Fridman WH, Sautes C. Effect of TGF-beta1 on cell cycle regulatory proteins in LPS-stimulated normal mouse Blymphocytes. J Immunol. 1997;159:4155–64.
38. Djaborkhel R, Tvrdik D, Eckschlager T, et al. Cyclin A down-regulation in TGFbeta1-arrested follicular lymphoma cells. Exp Cell Res. 2000;261:250–9.
39. Kehrl JH, Roberts AB, Wakefield LM, et al. Transforming growth factor beta is an important immunomodulatory protein for human Blymphocytes. J Immunol. 1986;137:3855–60.
40. Wahl SM, Hunt DA, Wong HL, et al. Transforming growth factor is a potent immunosuppressive agent that inhibits IL-1-dependent lymphocyte proliferation. J Immunol. 1988;140:3026–32.
41. Ranges GE, Figari IS, Espevik T, et al. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987;166:991–8.
42. Lotz M, Ranheim E, Kipps TJ. Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia Bcells. J Exp Med. 1994;179:999–1004.
43. Lebman DA, Edmiston JS. The role of TGF-beta in growth, differentiation, and maturation of Blymphocytes. Microbes Infect. 1999;1:1297–304.
44. Chaouchi N, Arvanitakis L, Auffredou MT, et al. Characterization of transforming growth factor-beta 1 induced apoptosis in normal human Bcells and lymphoma Bcell lines. Oncogene. 1995;11:1615–22.